NeoFuse

Phase 1/2Completed
0 watching 0 views this week๐Ÿ’ค Quiet
36
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cervical Degenerative Disc Disease

Conditions

Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis

Trial Timeline

Jun 1, 2010 โ†’ Mar 1, 2013

About NeoFuse

NeoFuse is a phase 1/2 stage product being developed by Mesoblast for Cervical Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01106417. Target conditions include Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT01097486Phase 2Completed
NCT01106417Phase 1/2Completed
NCT00549913Phase 1/2Completed

Competing Products

20 competing products in Cervical Degenerative Disc Disease

See all competitors
ProductCompanyStageHype Score
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePrecigenPhase 2
47
ABP-450AEON BiopharmaPhase 2
44
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
52
Amolimogene + AmolimogeneEisaiPhase 2/3
65
BOTULINUM TOXIN TYPE BEisaiPhase 2
52
Gemzar (gemcitabine)Eli LillyPhase 3
77
PemetrexedEli LillyPhase 2
52
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
52
camrelizumab๏ผ› famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
52
VolrustomigAstraZenecaPhase 3
77
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
77
VolrustomigAstraZenecaPhase 2
52